GlassScriptPhysician profile
Dragana Lovre
NPI 1649562604
$14,307.23
in general payments reported to CMS, 2019-2025
10 companies · $7,664 in 2025
The $7,664 reported for 2025 was more than what 89% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,996 · 2020: $96.81 · 2021: $300 · 2024: $2,250 · 2025: $7,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,500 · Consulting Fee: $2,250 · Food and Beverage: $588 · Travel and Lodging: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,500.00 |
| Consulting Fee | $2,250.00 |
| Food and Beverage | $587.64 |
| Travel and Lodging | $576.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $7,375.93 | 2025 | Mycapssa |
| Corcept Therapeutics | $3,996.08 | 2019 | |
| Novo Nordisk INC | $2,346.81 | 2020-2024 | |
| Abbott Laboratories | $300.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $149.07 | 2025 | Strensiq |
| Madrigal Pharmaceuticals | $116.01 | 2025 | Rezdiffra |
| Xeris Pharmaceuticals, INC. | $23.33 | 2025 | Recorlev |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dragana Lovre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.